The Expression of Melanoma-Associated Antigen D2 Both in Surgically Resected and Serum Samples Serves as Clinically Relevant Biomarker of Gastric Cancer Progression

Kanda, Mitsuro; Nomoto, Shuji; Oya, Hisaharu; Takami, Hideki; Shimizu, Dai; Hibino, Susumu; Hashimoto, R; Kobayashi, Daisuke; Tanaka, Chie; Yamada, Suguru; Fujii, Tsutomu; Nakayama, Goro; Sugimoto, Hiroyuki; Koike, Masahiko; Fujiwara, Michitaka; Kodera, Yasuhiro

doi:10.1245/s10434-015-4457-8

Cited by 44 publications

(38 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although palliative chemotherapy and surgery are beneficial, the outcome of GC remains dismal (4)(5)(6). The high mortality of GC is explained by our poor understanding of its mechanism of progression and the lack of suitable diagnostic markers that hinder diagnosis before the disease reaches an advanced stage (7,8). GC represents a biologically and genetically heterogeneous group of tumours that are induced by multiple factors that deregulate cell signalling pathways, which leads to the acquisition of malignant phenotypes such as increased cell proliferation, inhibition of apoptosis and enhanced invasiveness (9)(10)(11).…”

Section: Introductionmentioning

confidence: 99%

Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer

Kanda

Shimizu

Fujii

et al. 2016

International Journal of Oncology

Self Cite

View full text Add to dashboard Cite

Abstract. Identification of novel gastric cancer (GC)-related molecules is necessary to improve management of patients with GC in both diagnostic and therapeutic aspects. The aim of the present study was to determine whether protein arginine methyltransferase 5 (PRMT5) acts as an oncogene in the progression of GC and whether it serves as a novel diagnostic marker and therapeutic target. We conducted global expression profiling of GC cell lines and RNA interference experiments to evaluate the effect of PRMT5 expression on the phenotype of GC cells. We analysed tissues of 179 patients with GC to assess the association of PRMT5 mRNA levels with clinicopathological factors. Differential expression of PRMT5 mRNA by GC cell lines correlated positively with the levels of GEMIN2, STAT3 and TGFB3. PRMT5 knockdown reduced the proliferation, invasion and migration of a GC cell line. PRMT5 mRNA levels were significantly higher in GC tissues than the corresponding adjacent normal tissues and were independent of tumour depth, differentiation and lymph node metastasis. High PRMT5 expression was an independent risk factor of positive peritoneal lavage cytology (odds ratio 3.90, P=0.003) and decreased survival. PRMT5 enhances the malignant phenotype of GC cell lines and its expression in gastric tissues may serve as a biomarker for patient stratification and a potential target of therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer

Kanda

Shimizu

Fujii

et al. 2016

International Journal of Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, the identification of molecular biomarkers that predict treatment efficacy will likely improve our ability to manage these patients. 22 It is important to note that the outcome of the COMET trial is highly significant because of its data regarding safety and influence on PFS after liver resection. For example, the overall frequency of grade 3/4 AEs, including hematologic and nonhematologic events, was 45 %, which is generally consistent that of the new EPOC trial (preoperative cetuximab plus chemotherapy, 40 %) and an earlier clinical trial conducted in the United Kingdom.…”

Section: Discussionmentioning

confidence: 99%

The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…By contrast, the profile of prognostic factors was dramatically altered in patients who received S-1, with macroscopic tumor size ‡50 mm identified as the only significant prognostic factor [68]. A large body of evidence indicates that the depth of tumor invasion serves as an important prognostic factor for gastric cancer as a major determinant of tumor node metastasis staging, partially because serosal infiltration correlates with peritoneal recurrence [2,69,70]. Ultimately, these results emphasize that new methods for patient stratification will need to be established in patients who are receiving more intense treatments, such as curative gastrectomy followed by adjuvant chemotherapy, with the risk for recurrence.…”

Section: Alteration Of Recurrence Pattern and Prognostic Factors By Adjmentioning

confidence: 99%

Updated evidence on adjuvant treatments for gastric cancer

Kanda

Kodera

Sakamoto

2015

Expert Review of Gastroenterology & Hepatology

Self Cite

View full text Add to dashboard Cite

Gastric cancer is one of the main causes of cancer-related deaths worldwide. Even when diagnosed as a localized disease and resected with the intent to cure, recurrences frequently arise due to undetected or invisible micrometastases. Importantly, several proposed multimodal strategies to eliminate micrometastases have met some clinical success. However, while pivotal Phase III clinical trials comparing adjuvant therapies with surgery alone have confirmed the overall benefit of adjunctive treatments in patients with locally advanced gastric cancer, further improvement in postoperative outcomes is required, particularly in stage III disease. This review presents the current status of multimodal treatment strategies, with a particular focus on unresolved issues, based on updated literature searches and analysis of clinical trial databases.

show abstract

The Expression of Melanoma-Associated Antigen D2 Both in Surgically Resected and Serum Samples Serves as Clinically Relevant Biomarker of Gastric Cancer Progression

Abstract: MAGE-D2 was associated with metastatic potential of GC and may represent a promising biomarker, both in gastric tissues and serum samples, for malignant behavior of GC.

Cited by 44 publications

References 28 publications

Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer

Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer

The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer

Updated evidence on adjuvant treatments for gastric cancer

Contact Info

Product

Resources

About